NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...
This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary filed a voluntary prepackaged Chapter 11 bankruptcy case to resolve ...
S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's ...
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback